The AI Healthcare Divide: What Davos 2026 Missed About Global Inequality
Davos 2026 was wall-to-wall AI talk. Whether you were listening to heads of state or CEOs, the conversation kept circling back to how…
-
-
Is Pharmacogenomics Paired with AI the Antidote to the Global Cardiovascular Crisis?
Cardiovascular disease remains the world’s leading cause of death, claiming close to 20 million lives each year, with cases continuing to rise across…
-
Clinicians in Saudi Arabia “Know About” Pharmacogenomics, New Study Finds
Pharmacogenomics, or PGx, is changing medicine worldwide. The idea is simple: the right drug should match a person’s genes. But turning this idea…
-
New UK Guideline: Clopidogrel Now Requires Genetic Testing
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the…
-
Pharmacogenomics Is Transforming Drug Development and Patient Care: Insights from a Recent Study
Pharmacogenomics—the study of how an individual’s genetic makeup influences their response to medications—has become one of the most important pillars of modern personalized…
-
Rethinking Pharmacogenomics with Multi-Omics and AI
For decades, doctors have relied on trial and error to prescribe medications. Two patients with the same condition can respond in completely opposite…
-
Vega, Sirius, &The Future of Pharmacogenomics
Drug prescribing is entering a new chapter. For decades, clinicians have relied on broad guidelines, trial-and-error approaches, and limited genetic information to determine…
-
OneOme to Shutdown, Deal a Blow to PGx Industry Momentum
OneOme, a leading name in pharmacogenomics testing and personalized medicine, has announced that it will cease operations by November 14, 2025, citing ongoing…
-
The Three Key Factors Driving the Rise of Preemptive Pharmacogenomics
For years, pharmacogenomics (PGx) was seen as a future promise, a fascinating science that could someday make drug therapy safer and more effective….
-
FDA’s Final Rule on Laboratory-Developed Tests: Implications for Pharmacogenomics
In May 2024, the U.S. Food and Drug Administration (FDA) published a final rule that would bring laboratory-developed tests (LDTs) explicitly under the…
End of content
End of content